Core Viewpoint - Beilu Pharmaceutical (300016.SZ) plans to raise a total of no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, which does not exceed 20% of the company's net assets at the end of the last fiscal year [1] Fundraising Details - The total amount of funds raised will not exceed 300 million yuan, including the principal amount [1] - The net proceeds from the fundraising, after deducting related issuance costs, will be fully invested in the construction of the Luzhibao chemical drug production workshop and intelligent comprehensive warehouse project, as well as the technical transformation project for a new 100-ton iodinated methyl propyl and 50-ton iodinated butanol raw material production line, and to supplement working capital [1]

Group 1 - North Lu Pharmaceutical announced a stock issuance plan approved by the 2024 annual general meeting, aiming to raise no more than 300 million yuan [1] - The stock issuance will target no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [1] - The raised funds will be allocated to three main projects: approximately 234 million yuan for the construction of a pharmaceutical production workshop and smart warehouse, 39.86 million yuan for the renovation of a new production line for iodine-based raw materials, and 26.4 million yuan for working capital [1] Group 2 - As of the latest report, North Lu Pharmaceutical has a market capitalization of 4.9 billion yuan [2] - The company's revenue composition for 2024 indicates that 98.88% of its income will come from pharmaceutical production, while other business revenues will account for 1.12% [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) plans to issue shares to specific targets through a simplified procedure, aiming to raise no more than 300 million yuan for various projects and working capital [1] Group 1: Share Issuance Details - The company intends to issue shares to no more than 35 specific targets [1] - The issuance price will not be lower than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will be determined by the total amount of funds raised divided by the issuance price, not exceeding 30% of the company's total share capital before the issuance [1] Group 2: Fund Utilization - The total amount raised from the share issuance will not exceed 300 million yuan, including the principal [1] - After deducting related issuance costs, the net proceeds will be fully invested in the construction of the Luzhibao pharmaceutical production workshop and intelligent comprehensive warehouse project [1] - Additional investments will be made in the technical transformation project for a new 100-ton iodinated methylpyrrolidone and 50-ton iodinated butanol raw material production line, as well as to supplement working capital [1]

Core Viewpoint - Beilu Pharmaceutical (300016) plans to raise no more than 300 million yuan through a simplified procedure for specific investors, aimed at funding various projects including the production workshop and intelligent comprehensive warehouse for LZB pharmaceutical, a technical transformation project for 100 tons of Iodine Meperidine and 50 tons of Iodine Butanol raw material production lines, as well as supplementing working capital [1] Group 1 - The company intends to raise funds not exceeding 300 million yuan [1] - The raised funds will be allocated to the construction of a production workshop and intelligent warehouse [1] - The funding will also support the technical transformation of specific raw material production lines [1]